ReviewFrontiers in cardiovascular medicine2026
Emerging roles of spexin in cardiovascular homeostasis.
Review in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spexin (SPX) is a highly conserved, proteolytically processed 14-amino acid peptide hormone derived from spexin precursor, originally identified through a bioinformatics-based prediction algorithm. SPX possesses pleiotropic effects across multiple organ system and has been implicated in the regulation of appetite, lipid and glucose metabolism, reproduction, inflammation, oxidative stress, neuropsychiatric functions, and cardiovascular physiology, with emerging evidence indicating sex-dependent effects in reproduction and metabolism. SPX exerts its biological effects via galanin receptors, engaging diverse G-protein coupled receptor signaling pathways. Altered SPX expression has been observed in a range of metabolic and systemic conditions, including obesity and metabolic syndrome, type 2 diabetes, hypertension, anxiety and depression, chronic kidney disease, non-alcoholic fatty liver disease, and aging, among others, highlighting its potential as both a diagnostic biomarker and a therapeutic target. Recent research suggests that SPX contributes to cardiovascular homeostasis by modulating autonomic regulation, inflammatory response, cardiomyocyte apoptosis, vascular tone, carotid body chemoreception, lipid metabolism, and insulin sensitivity, all of which are critical for maintaining cardiovascular health. This review concisely summarizes the distribution and regulation of SPX, with a focus on its emerging roles in the pathogenesis of cardiovascular disease and its potential as a theranostic agent.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.